| Date |
Subject |
Media |
| 2025-07-15 |
Acer Medical’s “VeriOsteo OP” Obtains Regulatory Approval in Singapore
|
Acer Medical, the smart healthcare subsidiary of Acer Group, continues to expand its footprint in Southeast Asia. On July 3, the company announced that its AI-assisted diagnostic software for bone density abnormalities, VeriOsteo OP, has officially received marketing authorization from Singapore’s Health Sciences Authority (HSA). |
| 2025-07-15 |
Taipei Veterans General Hospital Reaches 500 Cases of Carbon Ion Therapy, With Pancreatic Cancer Leading and Drawing Patients from Southeast Asia
|
Taipei Veterans General Hospital (TVGH) has reached a significant milestone at its Heavy Particle Therapy Center, treating its 500th cancer patient. To mark the occasion, the medical team prepared a special farewell for the patient before his return home, celebrating the successful completion of his treatment. According to Dr. Yu-Ming Liu, Director of the Center for Heavy Particle and Radiation Oncology at TVGH, 90% of patients receiving this advanced therapy are from Taiwan, while the remaining 10% are international patients—primarily from Southeast Asia. Among the treated cancers, pancreatic cancer, known for its treatment difficulty, accounts for the largest share. |
| 2025-07-15 |
Yoda Therapeutics-KY’s Phase II MSA Clinical Trial Approved by Japan’s PMDA, Targeting Completion by 2026
|
Yoda Therapeutics-KY announced on the 2nd that its subsidiary’s application for a Phase II clinical trial of YA-101, a new drug candidate for the treatment of Multiple System Atrophy (MSA), has been approved by Japan’s Pharmaceuticals and Medical Devices Agency (PMDA). This follows previous approvals by the U.S. Food and Drug Administration (FDA) and Taiwan’s Food and Drug Administration (TFDA) last year. |
| 2025-07-15 |
Lin BioScience’s Oral Drug LBS-008 for Late-Stage Dry AMD Completes Global Phase 3 Enrollment
|
On July 2, Lin BioScience, through its subsidiary Belite Bio, Inc., announced that enrollment for the global Phase 3 clinical trial of its oral drug LBS-008 (Tinlarebant) for the treatment of geographic atrophy (GA), the advanced form of dry age-related macular degeneration (dry AMD), has been completed. A total of 500 participants were enrolled across the United States, United Kingdom, France, Czech Republic, Switzerland, mainland China, Taiwan, and Australia. Tinlarebant is positioned to become the world’s first oral treatment for GA, targeting a global market opportunity exceeding USD 20 billion. |
| 2025-07-15 |
Inventec’s AI Empowers Wound Care at Taichung Tzu Chi Hospital, Enhancing Medical Quality and Efficiency
|
On July 2, leading ODM manufacturer Inventec announced that its AI-powered medical device, “InSmart Wound Assessment Software” (TFDA Device License No. 008105), has been in service at Taichung Tzu Chi Hospital for nearly a year. The software has successfully supported the development of the hospital’s signature wound care program. From initial wound screening across the hospital to specialist nurse training applications, the software has reduced average wound assessment time by more than 40-fold. This year, Tzu Chi Medical Foundation plans to expand its use to long-term care centers, supporting home care and community-based specialist nurses in wound assessment—accelerating chronic disease care, alleviating workforce shortages, and improving long-term care quality. |
| 2025-07-15 |
Taipei Veterans General Hospital Reaches AI Diagnostic Milestone: Brain Imaging Identifies Schizophrenia with 91.7% Accuracy
|
Schizophrenia is a severe, chronic mental disorder affecting about 1% of the global population. Traditionally, diagnoses have relied primarily on behavioral assessments, and the medical community has long sought objective biological markers. Professor Chih-Chieh Yang from the Department of Psychiatry at Taipei Veterans General Hospital has led a team in developing an advanced “Smart Brain Imaging Platform” using cutting-edge medical AI technology. This platform assists in evaluating schizophrenia with an accuracy rate of 91.7%, earning a Gold Medal at the prestigious Edison Awards—known as the “Oscars of Innovation.” |
| 2025-07-15 |
Ever Supreme Bio Technology Celebrates Dual Milestones: Record-High June Revenue and Phase 2 Trial of UMSC01 Set for Q3 Launch
|
Ever Supreme Bio Technology has announced two major milestones. Thanks to sustained momentum in its cell therapy CDMO (Contract Development and Manufacturing Organization) orders, the company posted June consolidated revenue of NT$80.87 million, marking a 30% year-on-year growth and an 11% increase from the previous month—the highest June revenue in the company’s history. Cumulative revenue for the first half of the year has reached NT$398 million, and expectations for even stronger performance in the second half remain high, signaling continued positive growth momentum. |
| 2025-07-15 |
New Biomedical Player Joins the Market: LotusNine Medical Debuts on the Pioneer Stock Board, Focusing on Mobile AI Medical Devices
|
The Taipei Exchange’s Pioneer Stock Board welcomes a new addition in the biotech and healthcare category. LotusNine Medical Inc., a company integrating AI to develop innovative mobile medical devices and risk detection platforms, officially listed today (July 2). |
| 2025-07-15 |
Primo Biotechnology Completes Series A Funding, Targets Emerging Stock Board Listing by 2026
|
As global pharmaceutical giants Eli Lilly, AstraZeneca, and Novartis aggressively expand into the radiopharmaceutical market, Taiwan-based startup Primo Biotechnology Co., Ltd. is gaining momentum, announcing the successful completion of its Series A funding round. |
| 2025-07-15 |
Immunwork’s Long-Acting Octreotide Drug TE-8214 Shows Promising Results in Phase 1 Clinical Trial
|
Immunwork, founded by renowned immunologist Tse Wen Chang, announced on July 1 that its independently developed long-acting octreotide candidate TE-8214 has successfully completed its Phase 1 clinical trial in Australia. The results demonstrated good safety and tolerability, with the drug achieving its intended pharmacological mechanism. Additionally, subcutaneous injection was well tolerated and did not cause any injection-site reactions. |
